

# A Hugh Mostafid

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4835111/publications.pdf>

Version: 2024-02-01

109  
papers

5,587  
citations

159358

30  
h-index

85405

71  
g-index

113  
all docs

113  
docs citations

113  
times ranked

4920  
citing authors

#	ARTICLE	IF	CITATIONS
1	European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Tj ETQq1 1 0.784314 rgBT /Overlock 10	0.9	936
2	European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2017 Update. <i>European Urology</i> , 2018, 73, 111-122.	0.9	627
3	European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and) Tj ETQq1 1 0.784314 rgBT /Overlock 10	0.9	559
4	European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update. <i>European Urology</i> , 2021, 79, 62-79.	0.9	532
5	Prognostic Performance and Reproducibility of the 1973 and 2004/2016 World Health Organization Grading Classification Systems in Non-muscle-invasive Bladder Cancer: A European Association of Urology Non-muscle Invasive Bladder Cancer Guidelines Panel Systematic Review. <i>European Urology</i> , 2017, 72, 801-813.	0.9	205
6	EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer – An International Collaborative Multistakeholder Effort. <i>European Urology</i> , 2020, 77, 223-250.	0.9	132
7	Hexaminolevulinate-Guided Fluorescence Cystoscopy in the Diagnosis and Follow-Up of Patients with Non-muscle-Invasive Bladder Cancer: Review of the Evidence and Recommendations. <i>European Urology</i> , 2010, 57, 607-614.	0.9	117
8	Grading of Urothelial Carcinoma and The New World Health Organisation Classification of Tumours of the Urinary System and Male Genital Organs 2016. <i>European Urology Focus</i> , 2019, 5, 457-466.	1.6	112
9	Global Trends of Bladder Cancer Incidence and Mortality, and Their Associations with Tobacco Use and Gross Domestic Product Per Capita. <i>European Urology</i> , 2020, 78, 893-906.	0.9	112
10	Oncological Outcomes of Laparoscopic Nephroureterectomy Versus Open Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: An European Association of Urology Guidelines Systematic Review. <i>European Urology Focus</i> , 2019, 5, 205-223.	1.6	103
11	Quality Improvement in Multidisciplinary Cancer Teams: An Investigation of Teamwork and Clinical Decision-Making and Cross-Validation of Assessments. <i>Annals of Surgical Oncology</i> , 2011, 18, 3535-3543.	0.7	97
12	EAU-ESMO consensus statements on the management of advanced and variant bladder cancer – an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees. <i>Annals of Oncology</i> , 2019, 30, 1697-1727.	0.6	96
13	Radiofrequency-induced Thermo-chemotherapy Effect Versus a Second Course of Bacillus Calmette-Guérin or Institutional Standard in Patients with Recurrence of Non-muscle-invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-Guérin Therapy (HYMN): A Phase III, Open-label, Randomised Controlled Trial. <i>European Urology</i> , 2019, 75, 63-71.	0.9	96
14	Phase I Trial of an ICAM-1-Targeted Immunotherapeutic-Coxsackievirus A21 (CVA21) as an Oncolytic Agent Against Non Muscle-Invasive Bladder Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 5818-5831.	3.2	86
15	Planning percutaneous nephrolithotomy using multidetector computed tomography urography, multiplanar reconstruction and three-dimensional reformatting. <i>BJU International</i> , 2005, 95, 1280-1284.	1.3	84
16	Who Should Be Investigated for Haematuria? Results of a Contemporary Prospective Observational Study of 3556 Patients. <i>European Urology</i> , 2018, 74, 10-14.	0.9	78
17	An International Collaborative Consensus Statement on En Bloc Resection of Bladder Tumour Incorporating Two Systematic Reviews, a Two-round Delphi Survey, and a Consensus Meeting. <i>European Urology</i> , 2020, 78, 546-569.	0.9	77
18	Guideline of guidelines: asymptomatic microscopic haematuria. <i>BJU International</i> , 2018, 121, 176-183.	1.3	76

#	ARTICLE	IF	CITATIONS
19	Potential Benefit of Lymph Node Dissection During Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review by the European Association of Urology Guidelines Panel on Non-muscle-invasive Bladder Cancer. <i>European Urology Focus</i> , 2019, 5, 224-241.	1.6	74
20	Risk Stratification Tools and Prognostic Models in Non-muscle-invasive Bladder Cancer: A Critical Assessment from the European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel. <i>European Urology Focus</i> , 2020, 6, 479-489.	1.6	72
21	BCG immunotherapy for bladder cancer—the effects of substrain differences. <i>Nature Reviews Urology</i> , 2013, 10, 580-588.	1.9	65
22	Therapeutic Options in High-risk Non-muscle-invasive Bladder Cancer During the Current Worldwide Shortage of Bacille Calmette-Guérin. <i>European Urology</i> , 2015, 67, 359-360.	0.9	62
23	Can Renal and Bladder Ultrasound Replace Computerized Tomography Urogram in Patients Investigated for Microscopic Hematuria?. <i>Journal of Urology</i> , 2018, 200, 973-980.	0.2	62
24	Advances in intravesical drug delivery systems to treat bladder cancer. <i>International Journal of Pharmaceutics</i> , 2017, 532, 105-117.	2.6	58
25	Hyperthermic Intravesical Chemotherapy for BCG Unresponsive Non-Muscle Invasive Bladder Cancer Patients. <i>Bladder Cancer</i> , 2018, 4, 395-401.	0.2	55
26	Prognostic Value of the WHO1973 and WHO2004/2016 Classification Systems for Grade in Primary Ta/T1 Non-muscle-invasive Bladder Cancer: A Multicenter European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel Study. <i>European Urology Oncology</i> , 2021, 4, 182-191.	2.6	54
27	A core outcome set for localised prostate cancer effectiveness trials. <i>BJU International</i> , 2017, 120, E64-E79.	1.3	48
28	Prevention of bladder cancer incidence and recurrence. <i>Current Opinion in Urology</i> , 2018, 28, 88-92.	0.9	44
29	The self-expanding metallic ureteric stent in the long-term management of benign ureteric strictures. <i>BJU International</i> , 2001, 88, 339-342.	1.3	43
30	Measuring and improving the quality of transurethral resection for bladder tumour (TURBT). <i>BJU International</i> , 2012, 109, 1579-1582.	1.3	35
31	Transurethral Resection of Bladder Tumour: The Neglected Procedure in the Technology Race in Bladder Cancer. <i>European Urology</i> , 2020, 77, 669-670.	0.9	30
32	The IDENTIFY study: the investigation and detection of urological neoplasia in patients referred with suspected urinary tract cancer—a multicentre observational study. <i>BJU International</i> , 2021, 128, 440-450.	1.3	30
33	Combination of a fusogenic glycoprotein, pro-drug activation and oncolytic HSV as an intravesical therapy for superficial bladder cancer. <i>British Journal of Cancer</i> , 2012, 106, 496-507.	2.9	28
34	BOXIT—A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004). <i>European Urology</i> , 2019, 75, 593-601.	0.9	27
35	Papillary urothelial neoplasm of low malignant potential (PUN-LMP): Still a meaningful histo-pathological grade category for Ta, noninvasive bladder tumors in 2019?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 440-448.	0.8	27
36	CALIBER: a phase II randomized feasibility trial of chemoablation with mitomycin vs surgical management in low-risk non-muscle-invasive bladder cancer. <i>BJU International</i> , 2020, 125, 817-826.	1.3	27

#	ARTICLE	IF	CITATIONS
37	Best Practices to Optimise Quality and Outcomes of Transurethral Resection of Bladder Tumours. <i>European Urology Oncology</i> , 2021, 4, 12-19.	2.6	26
38	No "one size fits all"™ approach in the management of high-risk non-muscle invasive bladder cancer. <i>Scandinavian Journal of Urology</i> , 2021, 55, 53-53.	0.6	26
39	The responsiveness of the ICSmale questionnaire to outcome: evidence from the ICS-â€BPHâ€™ study. <i>BJU International</i> , 2001, 83, 243-248.	1.3	25
40	Immediate administration of intravesical mitomycin C after tumour resection for superficial bladder cancer. <i>BJU International</i> , 2006, 97, 509-512.	1.3	25
41	Does urinary cytology have a role in haematuria investigations?. <i>BJU International</i> , 2019, 123, 74-81.	1.3	25
42	Systematic Review of the Incidence of and Risk Factors for Urothelial Cancers and Renal Cell Carcinoma Among Patients with Haematuria. <i>European Urology</i> , 2022, 82, 182-192.	0.9	25
43	Treatment options and results of adjuvant treatment in nonmuscle-invasive bladder cancer (NMIBC) during the Bacillus Calmetteâ€GuÃ©rin shortage. <i>Current Opinion in Urology</i> , 2020, 30, 365-369.	0.9	23
44	Long-term efficacy of hyperthermic intravesical chemotherapy for BCG-unresponsive non-muscle invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 62.e13-62.e20.	0.8	21
45	The 2-year symptomatic and urodynamic results of a prospective randomized trial of interstitial radiofrequency therapy vs transurethral resection of the prostate. <i>BJU International</i> , 2001, 88, 217-220.	1.3	20
46	Development and validation of a haematuria cancer risk score to identify patients at risk of harbouring cancer. <i>Journal of Internal Medicine</i> , 2019, 285, 436-445.	2.7	20
47	Emerging Immunotherapy Options for bacillus Calmette-GuÃ©rin Unresponsive Nonmuscle Invasive Bladder Cancer. <i>Journal of Urology</i> , 2019, 202, 1111-1119.	0.2	20
48	A prospective randomized trial of interstitial radiofrequency therapy versus transurethral resection for the treatment of benign prostatic hyperplasia. <i>BJU International</i> , 1997, 80, 116-122.	1.3	18
49	What to do during Bacillus Calmetteâ€GuÃ©rin shortage? Valid strategies based on evidence. <i>Current Opinion in Urology</i> , 2018, 28, 570-576.	0.9	18
50	Exploring patientsâ€™ experience and perception of being diagnosed with bladder cancer: a mixedâ€methods approach. <i>BJU International</i> , 2020, 125, 669-678.	1.3	18
51	Photodynamic versus white light-guided treatment of non-muscle invasive bladder cancer: a study protocol for a randomised trial of clinical and cost-effectiveness. <i>BMJ Open</i> , 2019, 9, e022268.	0.8	16
52	Protocol for tumour-focused dose-escalated adaptive radiotherapy for the radical treatment of bladder cancer in a multicentre phase II randomised controlled trial (RAIDER): radiotherapy planning and delivery guidance. <i>BMJ Open</i> , 2020, 10, e041005.	0.8	16
53	Falling bladder cancer incidence from 1990 to 2009 is not producing universal mortality improvements. <i>Journal of Clinical Urology</i> , 2014, 7, 90-98.	0.1	15
54	Measles, mumps and rubella - the urologist's perspective. <i>International Journal of Clinical Practice</i> , 2006, 60, 335-339.	0.8	14

#	ARTICLE	IF	CITATIONS
55	Mesh erosion following laparoscopic incisional hernia repair. <i>Hernia: the Journal of Hernias and Abdominal Wall Surgery</i> , 2012, 16, 223-226.	0.9	14
56	So Much Cost, Such Little Progress. <i>European Urology</i> , 2014, 66, 263-264.	0.9	13
57	Diagnostic accuracy of ultrasonography, computed tomography, cystoscopy and cytology to detect urinary tract malignancies in patients with asymptomatic hematuria. <i>World Journal of Urology</i> , 2021, 39, 97-103.	1.2	13
58	IS IT TIME TO REDESIGN THE HAEMATURIA CLINIC?. <i>BJU International</i> , 2010, 105, 585-588.	1.3	12
59	Mixed methods approach to exploring patients' perspectives on the acceptability of a urinary biomarker test in replacing cystoscopy for bladder cancer surveillance. <i>BJU International</i> , 2019, 124, 408-417.	1.3	12
60	En-bloc resection of bladder tumour as primary treatment for patients with non-muscle-invasive bladder cancer: routine implementation in a multi-centre setting. <i>World Journal of Urology</i> , 2021, 39, 3353-3358.	1.2	12
61	The role of hexylaminolaevulinate in the diagnosis and follow-up of non-muscle-invasive bladder cancer. <i>BJU International</i> , 2010, 105, 2-7.	1.3	11
62	Therapeutic options in the management of intermediate-risk non-muscle-invasive bladder cancer. <i>BJU International</i> , 2009, 103, 726-729.	1.3	9
63	Reply to Harry Herr's Letter to the Editor re: Marko Babjuk, Andreas Böhle, Maximilian Burger, et al. EAU Guidelines on Non-muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. <i>Eur Urol</i> 2017;71:447-61. <i>European Urology</i> , 2017, 71, e173-e174.	0.9	9
64	Urothelial cancer: a narrative review of the role of novel immunotherapeutic agents with particular reference to the management of non-muscle-invasive disease. <i>BJU International</i> , 2019, 123, 947-958.	1.3	9
65	Rapid, Low-Cost Dielectrophoretic Diagnosis of Bladder Cancer in a Clinical Setting. <i>IEEE Journal of Translational Engineering in Health and Medicine</i> , 2020, 8, 1-5.	2.2	9
66	What influences adherence to guidance for postoperative instillation of intravesical chemotherapy to patients with bladder cancer?. <i>BJU International</i> , 2021, 128, 225-235.	1.3	9
67	IMPROVED DETECTION AND REDUCED EARLY RECURRENCE OF NON-MUSCLE-INVASIVE BLADDER CANCER USING HEXAMINOLAEVULINATE FLUORESCENCE CYSTOSCOPY: RESULTS OF A MULTICENTRE PROSPECTIVE RANDOMIZED STUDY (PC B305). <i>BJU International</i> , 2009, 104, 889-890.	1.3	8
68	Indication for a Single Postoperative Instillation of Chemotherapy in Non-muscle-invasive Bladder Cancer: What Factors Should Be Considered?. <i>European Urology Focus</i> , 2018, 4, 525-528.	1.6	8
69	Consensus Definition and Prediction of Complexity in Transurethral Resection or Bladder Endoscopic Dissection of Bladder Tumours. <i>Cancers</i> , 2020, 12, 3063.	1.7	7
70	Do patients with frank haematuria referred under the two-week rule have a higher incidence of bladder cancer?. <i>Annals of the Royal College of Surgeons of England</i> , 2005, 87, 345-347.	0.3	7
71	The Use of the NMP22 BladderChek Test for Bladder Cancer to Optimise Investigations in a One-Stop Haematuria Clinic. <i>British Journal of Medical and Surgical Urology</i> , 2008, 1, 126-130.	0.2	6
72	IDENTIFY: The investigation and detection of urological neoplasia in patients referred with suspected urinary tract cancer: A multicentre cohort study. <i>International Journal of Surgery Protocols</i> , 2020, 21, 8-12.	0.5	6

#	ARTICLE	IF	CITATIONS
73	Leydig cell tumour of the testis: a rare cause of male infertility. BJU International, 1998, 81, 651-651.	1.3	5
74	The management of hydronephrosis in patients undergoing TURBT. International Urology and Nephrology, 2007, 38, 483-486.	0.6	5
75	Phase I/II canon study: Oncolytic immunotherapy for the treatment of non-muscle invasive bladder (NMIBC) cancer using intravesical coxsackievirus A21.. Journal of Clinical Oncology, 2016, 34, e16016-e16016.	0.8	5
76	Does the Nonurologic Scientific Community Understand Urothelial Bladder Cancer?. European Urology, 2014, 66, 601-602.	0.9	4
77	T1G1 Bladder Cancer: Prognosis for this Rare Pathological Diagnosis Within the Nonâ€‘muscle-invasive Bladder Cancer Spectrum. European Urology Focus, 2022, , .	1.6	4
78	Interstitial Radiofrequency Therapy of the Prostate: Results of a Pilot Study. Journal of Urology, 1996, 155, 1946-1949.	0.2	3
79	The testicular 'tumour' of adrenogenital syndrome: an unusual cause of male infertility. BJU International, 1998, 81, 649-650.	1.3	3
80	Radio-Contrast Enhancement of a Urinary Tract Calculus. Urologia Internationalis, 1999, 62, 127-129.	0.6	3
81	Emergency dorsal slit for balanitis with retention. Journal of the Royal Society of Medicine, 2004, 97, 205-206.	1.1	3
82	Case report: differential diagnosis of isolated iliac lymphadenopathy following Bacillus Calmette-GuÃ©rin treatment for high-risk superficial bladder cancer. International Urology and Nephrology, 2007, 39, 1039-1041.	0.6	3
83	Diagnosis and treatment of non-muscle-invasive bladder cancer. Trends in Urology & Men's Health, 2015, 6, 23-27.	0.2	3
84	Time to reâ€‘evaluate and refine reâ€‘transurethral resection in bladder cancer?. BJU International, 2016, 118, 9-10.	1.3	3
85	Genetic polymorphisms may explain association between alcohol consumption and bladder cancer risk in East Asian men. Translational Andrology and Urology, 2018, 7, S252-S254.	0.6	3
86	Indications and Complications of Androgen Deprivation Therapy. Seminars in Oncology Nursing, 2020, 36, 151042.	0.7	3
87	Alternating Cystoscopy with Bladder EpiCheckÂ® in the Surveillance of Low-Grade Intermediate-Risk NMIBC: A Cost Comparison Model. Bladder Cancer, 2021, 7, 307-315.	0.2	3
88	Management of <scp>NMIBC</scp> during <scp>BCG</scp> shortage and <scp>COVID</scp>â€‘19. Trends in Urology & Men's Health, 2021, 12, 7-11.	0.2	3
89	A novel device for reconstituting and delivering intravesical chemotherapy. BJU International, 2003, 92, 492-492.	1.3	2
90	RE: A SINGLE IMMEDIATE POSTOPERATIVE INSTILLATION OF CHEMOTHERAPY DECREASES THE RISK OF RECURRENCE IN PATIENTS WITH STAGE Ta T1 BLADDER CANCER: A META-ANALYSIS OF PUBLISHED RESULTS OF RANDOMIZED CLINICAL TRIALS. Journal of Urology, 2005, 173, 1433-1433.	0.2	2

#	ARTICLE	IF	CITATIONS
91	Neoadjuvant Intravesical Therapy for Non-muscle-invasive Bladder Cancer: A New Approach for Old Agents?. <i>European Urology</i> , 2020, 78, 863-864.	0.9	2
92	THE BAUS UROLOGICAL CANCER OBSERVATORY. <i>BJU International</i> , 2009, 104, 562-562.	1.3	1
93	The Safe and Economical Care of Ta Bladder Cancer. <i>Urology Practice</i> , 2014, 1, 176-183.	0.2	1
94	T1 High-grade Bladder Cancer: The Search for the Optimal Management Continues. <i>European Urology</i> , 2018, 74, 609-610.	0.9	1
95	Intravesical BCG: where do we stand? Past, present and future. <i>Journal of Clinical Urology</i> , 2019, 12, 425-435.	0.1	1
96	Cystoscopic surveillance for bladder cancer: Learning the lessons forced upon us by the Covid-19 pandemic*. <i>Scandinavian Journal of Urology</i> , 2020, 54, 367-368.	0.6	1
97	Early recurrence and the need for re-resection following Photodynamic diagnosis-assisted Transurethral Resection of Bladder Tumours: Multi-centre real-world experience of the UK PDD Users Group. <i>Journal of Clinical Urology</i> , 2021, 14, 65-72.	0.1	1
98	RE: POSSIBLE MECHANISMS OF ACTION OF TRANSURETHRAL NEEDLE ABLATION OF THE PROSTATE ON BENIGN PROSTATIC HYPERPLASIA SYMPTOMS A NEUROHISTOCHEMICAL STUDY. <i>Journal of Urology</i> , 1998, 159, 209-210.	0.2	0
99	Immediate Postoperative Instillation of Intravesical Mitomycin in Theatre: Outcome and Effect on Recurrence of Non Muscle-Invasive Bladder Cancer. <i>Current Urology</i> , 2009, 3, 72-75.	0.4	0
100	Editorial Comment to Maintenance intravesical bacillus Calmette-Guérin instillation for Ta, T1 cancer and carcinoma <i>in situ</i> of the bladder: Randomized controlled trial by the BCG Tokyo Strain Study Group. <i>International Journal of Urology</i> , 2010, 17, 766-767.	0.5	0
101	Predicting Outcomes in Bladder Cancer: Are We Any Good and Could We Do Better?. <i>European Urology</i> , 2015, 68, 254-255.	0.9	0
102	Is 4 days hospital stay post robotic radical cystectomy feasible; A multidisciplinary enhanced recovery program after minimal invasive surgery challenge. <i>Clinical Nutrition ESPEN</i> , 2017, 19, 79.	0.5	0
103	PD36-06 IS FOUR DAYS HOSPITAL STAY AFTER ROBOTIC ASSISTED RADICAL CYSTECTOMY FEASIBLE? A MULTIDISCIPLINARY ENHANCED RECOVERY PROGRAM CHALLENGE. <i>Journal of Urology</i> , 2017, 197, .	0.2	0
104	PD19-08 RADIOFREQUENCY-INDUCED THERMO-CHEMOTHERAPY EFFECT (RITE) PLUS MITOMYCIN VERSUS A SECOND COURSE OF BACILLUS CALMETTE-GUÉRIN (BCG) OR INSTITUTIONAL STANDARD IN PATIENTS WITH RECURRENCE OF NON-MUSCLE INVASIVE BLADDER CANCER FOLLOWING INDUCTION OR MAINTENANCE BCG THERAPY (HYMN): A OPEN-LABEL, MULTICENTRE, PHASE III RANDOMISED CONTROLLED TRIAL. <i>Journal of Urology</i> , 2017, 197, .	0.2	0
105	Correction to: Meeting abstracts from the 4th International Clinical Trials Methodology Conference (ICTMC) and the 38th Annual Meeting of the Society for Clinical Trials. <i>Trials</i> , 2018, 19, .	0.7	0
106	The beginning of the end for asymptomatic microscopic haematuria. <i>Scandinavian Journal of Urology</i> , 2019, 53, 7-7.	0.6	0
107	The inflammatory potential of diet and bladder cancer risk: results from a prospective cohort study. <i>Translational Andrology and Urology</i> , 2019, 8, S491-S492.	0.6	0
108	TULA in recurrent non-muscle invasive bladder cancer. <i>Trends in Urology &amp; Men's Health</i> , 2020, 11, 18-19.	0.2	0

#	ARTICLE	IF	CITATIONS
109	En Bloc Resection of Bladder Tumor—Is It the Way Forward?. <i>Frontiers in Surgery</i> , 2021, 8, 685506.	0.6	0